• Regentis Biomaterials received a Notice of Allowance from Japan for a patent covering an organic solvent-free GelrinC manufacturing process.
• Claims cover protein-polymer conjugate compositions, manufacturing methods, ready-to-use liquid formulation for its cell-free knee cartilage repair hydrogel.
• Company cited manufacturing gains including a 5x yield increase, improved scalability, simplified production, enhanced environmental profile.
• Move expands GelrinC patent protection in Japan as Regentis advances Europe commercialization, passes 50% enrollment in its pivotal U.S. trial.
• Independent estimates put Japan’s cartilage repair market near USD 289 million by 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607200900ACCESSWRNAPR_____1193281) on July 20, 2026, and is solely responsible for the information contained therein.